ResMed Inc. Set to Report Strong Q1 2026 Earnings
ResMed Inc., a San Diego-based medical device and software company, is set to unveil its fiscal Q1 2026 earnings soon. The company has been performing well, with its stock market and earnings per share (EPS) expected to grow.
Wall Street analysts have a 'Moderate Buy' rating for ResMed Inc.'s stock market, with a mean price target of $290.92, indicating a potential 3.4% upside from current levels. They anticipate EPS of $2.49 in Q1 2026, a 13.2% increase from the year-ago quarter. ResMed Inc. has consistently surpassed analysts' bottom-line estimates in the last four quarters.
ResMed Inc.'s shares have surged 20.3% over the past 52 weeks, outpacing both the S&P 500 Index and the Health Care Select Sector SPDR Fund. For fiscal 2026, analysts expect a profit of $10.80 per share, representing a 13.1% increase from fiscal 2025. The company's strong performance is reflected in its market cap of $41.1 billion.
ResMed Inc. is scheduled to announce its fiscal Q1 2026 earnings soon. Analysts predict a positive outlook, with EPS growth and a 'Moderate Buy' rating for the company's stock market. The company's consistent earnings beats and stock market performance indicate a strong trajectory.
Read also:
- Regensburg Customs Crackdown Nets 40+ Violations in Hotel Industry
- Mural at blast site in CDMX commemorates Alicia Matías, sacrificing life for granddaughter's safety
- Germany Boosts EV Charging: 1,000 Fast-Charging Points on Motorways by 2026
- Albanese Invites LuLu Group to Australia as Free Trade Deal Takes Effect
